ArticleScientific reports2025
Synergistic antifungal and anti-aflatoxigenic effects of lactic acid bacteria and golden berry in a functional high-protein beverage.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-protein beverages are valued for their health benefits, but they face threats from toxigenic fungi and mycotoxins This study developed a novel, functional high-protein beverage (HPB) by synergistically combining whey protein concentrate (WPC), fermented by specific bacteria, with Physalis peruviana (golden berry) powder (at a 1:5; w/w). Three bacterial strains-Lactobacillus plantarum (BS-2), L. pentosus (BS-1), and L. paracasei (BS-3)-were involved for the fermentation, individually and in combinations. Fortification with golden berry significantly enhanced the phytochemical profile, increasing phenolic content (22.97 ± 0.56 mg GAE/g), flavonoids (97.15 ± 2.58 mg QE/g), and antioxidant capacity compared to the control. The BS-2 strain exhibited the strongest antifungal activity, inhibiting fungal growth by 53.8 ± 0.41% and completely suppressing the aflatoxin B
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.